Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today
The stock market was once again mixed on Thursday, with the Dow Jones Industrials gaining ground to set a record high for the third session in a row even as other major benchmarks lagged behind. Market participants turned their attention to the interest rate arena today, weighing the prospects for another rate hike from the Federal Reserve. Although most economists believe that the impact of the two major hurricanes that have hit the U.S. over the past month will forestall any September increase from the Fed, the possibility of an increase in December is still on the table. Today's data on consumer prices showed some signs of inflation, which could give the Fed room to hike rates.
Beyond that, investors focused largely on individual stocks today, and Halozyme Therapeutics (NASDAQ: HALO), Tenet Healthcare (NYSE: THC), and AMC Entertainment Holdings (NYSE: AMC) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.
Shares of Halozyme Therapeutics jumped 21% after the biotechnology company announced two major collaborations with larger peers in the healthcare space. Halozyme said that it had entered into a collaboration and licensing agreement with Bristol-Myers Squibb (NYSE: BMY) covering Halozyme's Enhanze drug-delivery technology, with terms including an initial $105 million payment and the potential to earn as many as 11 separate milestone payments of up to $160 million each if the collaboration reaches certain targets. Separately, Halozyme also licensed Enhanze to Roche for an initial $30 million payment, with its own milestone payment prospects of up to $160 million. Halozyme already had an arrangement with Roche, but the new deal with Bristol-Myers Squibb makes it clear just how promising Enhanze is to the industry.
Source: Fool.com
Bristol-Myers Squibb Aktie
Derzeit ist die Community gegenüber der Bristol-Myers Squibb Aktie mit 8 Buy-Einschätzungen und 3 Sell-Einschätzungen positiv gestimmt.
Das Community-Kursziel von 65 € für Bristol-Myers Squibb deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 43.66 € hin.
